Application of improved GalNAc conjugation in development of cost-effective siRNA therapies targeting cardiovascular diseases.
Li Q, Yin K, Ma HP, Liu HH, Li S, Luo X, Hu R, Zhang WW, Lv ZS, Niu XL, Gu MH, Li CL, Liu YS, Liu YJ, Li HB, Li N, Li C, Gu WW, Li JJ.
Li Q, et al. Among authors: niu xl.
Mol Ther. 2024 Mar 6;32(3):637-645. doi: 10.1016/j.ymthe.2024.01.008. Epub 2024 Jan 10.
Mol Ther. 2024.
PMID: 38204163